Cancer name Ovarian Cancer
Cancer Type OV
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment Trastuzumab
Drugstatus Approved, Investigational
Drugbank ID DB00072
Checkpoints NA
Signature Type Protein
Signature NRF2
Official Symbol NFE2L2
Mode of action PROT_NR_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description This demonstrates that NRF2 activation is not onlyimplicated in resistance to genotoxic agents as previously shown but can also lead to resistance to immunotherapies involving Pertuzumab and Trastuzumab, whose actionsare very specific to HER2 receptors and unrelated to antioxi-dant pathway until this study.
PMID 26770651
Title NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.